CPC C07K 16/1018 (2013.01) [A61K 31/13 (2013.01); A61K 31/215 (2013.01); A61K 31/7012 (2013.01); A61K 39/3955 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); C12P 21/005 (2013.01); G01N 33/56983 (2013.01); G01N 33/577 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/624 (2013.01); C07K 2317/626 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/11 (2013.01)] | 20 Claims |
1. An isolated antibody or a binding fragment thereof that is capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus, wherein the antibody or fragment thereof includes a set of six CDRs: HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 in which the set of six CDRs comprises the HCDR1 of SEQ ID NO.: 103, the HCDR2 of SEQ ID NO.: 104, the HCDR3 of SEQ ID NO.: 105, the LCDR1 of SEQ ID NO.: 108, the LCDR2 of SEQ ID NO.: 109 and-the LCDR3 of SEQ ID NO.: 110.
|